Bactiguard Holding Ab · OMXSTO:BACTI_B
Bactiguard Holding Ab — SEB Healthcare Seminar 2024
13 slides from Bactiguard Holding Ab's conference presentation, Nov 19, 2024
Slide 1: SEB Healthcare Seminar
SEB Healthcare Seminar 19 November 2024 Christine Lind, CEO
Slide 2: Bactiguard in brief
Bactiguard in brief Q&A advanced technology to established license potential in future prevent medical device partnerships with global license partnerships related infections MedTech giants across therapeutic areas 2
Slide 3: Advanced technology to prevent medical device related infections
Advanced technology to prevent medical device related infections Reduces microbial adhesion and biofilm formation • Biocompatible, safe and proven – reduces the risk of medical device related infections • Ultra-thin noble metal coating technology; gold, silver and palladium • In contact with fluids,
Slide 4: A knowledge and specialist organization
A knowledge and specialist organization Strategic focus areas to achieve profitable and sustainable growth R&D License Medical Wound Management partnerships portfolio Regulatory Focus going forward Advance current and Deliver competencies to Grow profitably develop future enhance partnerships 5
Slide 5: Opportunities to prevent infections across therapeutic areas
Opportunities to prevent infections across therapeutic areas Market opportunity (USD 80bn) Infection rates (Mortality %) 1-10% per procedure (2-10%) Orthopedics 40 Fracture related 30% (Trauma) Urology 3 CAUTI 12-24% (>2 days) (1-4%) CLABSI 4-6% (12-25%) Intravascular and endotracheal interventions
Slide 6: Business model and partner journey
Business model and partner journey Three types of revenues – partners generating exclusivity and license revenues are communicated 9
Slide 7: BD (Becton, Dickinson and Company)
BD (Becton, Dickinson and Company) One of the largest global MedTech companies in the world Relationship overview • Partnership since early 90s • ~245 million Bactiguard coated foley catheters sold by BD • Signed exclusive global license (ex China) agreement late 2023 extending markets for Bactiguar
Slide 8: Zimmer Biomet
Zimmer Biomet A global leader in orthopedics – comprehensive portfolio designed to maximize mobility and improve health Relationship overview • Partnership since 2019 • Trauma implant ZNN Bactiguard on market ─ rolled out across Europe – strong recognition and demand ─ introduced in Japan • Infectio
Slide 9: Wound Management by Bactiguard
Wound Management by Bactiguard Preventing infections by offering effective, biocompatible solutions to improve healing Offering includes VIGIMESH® • Hydrocyn aqua, an innovative wound care product enabling wound healing and preventing infection • A wide range of surgical sutures including specialist
Slide 10: Net sales grew 48% in Q3 and 23% YTD, driven by solid growth in license revenues
Net sales grew 48% in Q3 and 23% YTD, driven by solid growth in license revenues Net sales distribution SEK million BIP portfolio Wound Management portfolio License revenues Third quarter (Jul-Sep) Year to date (Jan-Sep) Full year RTM 235 +23% 23 202 179 31 59 13 145 45 54 20 +48% 40 67 153 45 2 120
Slide 11: EBITDA grew to 9.9 MSEK in Q3 and to 9.6 MSEK YTD
EBITDA grew to 9.9 MSEK in Q3 and to 9.6 MSEK YTD EBITDA SEK million Third quarter (Jul-Sep) Year to date (Jan-Sep) Full year RTM +19.4 +81.4 9.9 9.6 5.3 -9.5 -71.8 -76.1 2023 2024 2023 2024 2023 2023/24 14 Source: Bactiguard Holding AB, Interim report Q3 2024, p. 17
Slide 12: Our priorities ahead
Our priorities ahead Vision: become the global standard of care for preventing medical device related infections • Advance current partnerships – with BD, Zimmer Biomet and Well Lead • New partnerships in strategic therapeutic areas – convert early-stage projects into exclusivity and license partner
Slide 13: Q&A
Q&A Q&A to champion a healthier world by preventing infections 17